CRISPR CAR T-Cell Therapy: A Long-Term Study for Blood and Solid Cancers

What is CRISPR CAR T-Cell Therapy?

CRISPR CAR T-cell therapy is an innovative treatment approach that combines two cutting-edge technologies in cancer treatment: CRISPR gene editing and CAR (Chimeric Antigen Receptor) T-cell therapy. This treatment is being studied for its potential to fight various types of cancer, including blood cancers and solid tumors1.

In this therapy, T-cells (a type of immune cell) are taken from a donor (allogeneic means from someone other than the patient). These cells are then genetically modified using CRISPR/Cas9 technology to create special receptors on their surface called CARs. These CARs are designed to recognize and target a specific protein (in this case, CD19) found on cancer cells1.

Target Conditions

The CRISPR CAR T-cell therapy being studied is aimed at treating two broad categories of cancer1:

• Hematologic Malignancies: These are cancers that affect the blood, bone marrow, and lymph nodes. Examples include leukemia, lymphoma, and multiple myeloma.
• Solid Malignancies: These are cancers that form solid tumors in various parts of the body, such as the lungs, breast, or colon.

Study Objectives

The main goal of this long-term follow-up study is to evaluate the safety and effectiveness of CRISPR CAR cellular therapy in patients with blood cancers and solid tumors over an extended period (up to 15 years)1. The study has two primary objectives:

1. Long-term Safety: To assess any potential long-term side effects or complications that may arise from the treatment.
2. Long-term Efficacy: To determine how well the treatment continues to work over time in controlling or eliminating cancer.

Eligibility Criteria

To participate in this long-term follow-up study, patients must meet the following criteria1:

• Be able to understand and comply with the study procedures
• Voluntarily sign an informed consent document
• Have previously received CRISPR CAR cellular therapy

Importantly, there are no specific exclusion criteria mentioned for this study, which suggests that it aims to include a wide range of patients who have undergone this treatment1.

Study Endpoints

The study will measure several outcomes to assess the therapy's long-term effects1:

1. Primary Endpoint: The occurrence of side effects, including:
   • Serious adverse events related to the CRISPR CAR cellular therapy
   • Adverse events of special interest
2. Secondary Endpoints:
   • Overall survival: How long patients live after receiving the treatment
   • Duration of remission/response: How long the cancer remains controlled or undetectable after treatment

Drug Information

The specific drug being studied in this trial is called CTX1101. Here are some key details about this treatment:

• Full Name: Allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting CD19 antigen
• Form: Dispersion for infusion (a liquid form that is given directly into the bloodstream)
• Administration Route: Intravenous (through a vein)
• Manufacturer: CRISPR Therapeutics AG

This therapy is considered a cell therapy, which means it uses living cells as a treatment. In this case, the cells are T-cells that have been genetically modified to target cancer cells more effectively1.